School of Medicine
Dermatology | Hemic and Immune Systems | Heterocyclic Compounds | Neoplasms | Pharmaceutical Preparations | Skin and Connective Tissue Diseases | Therapeutics
Imiquimod is a topical immunomodulator used for the treatment of viral warts and superficial basal cell carcinoma and as an emerging therapy for lentigo maligna and cutaneous melanoma metastases. Vitiligo-like depigmentation has been described as a local adverse effect of topical imiquimod therapy for melanoma1 and at distant sites in patients treated with combination topical monobenzone-imiquimod for metastatic melanoma.2 We present a case in which topical imiquimod resulted in both the resolution of in-transit metastatic melanoma and the depigmentation of local and regional skin, suggesting a regional lymphatic effect of this localized topical treatment.
CT, computed tomography, depigmentation, imiquimod, in-transit metastases, melanoma, vitiligo
Rights and Permissions
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
DOI of Published Version
JAAD Case Rep. 2019 Apr 29;5(5):427-429. doi: 10.1016/j.jdcr.2019.03.015. eCollection 2019 May. Link to article on publisher's site
JAAD case reports
Tkachenko E, Lin JY, Hartman RI. (2019). Regional vitiligo induced by imiquimod treatment for in-transit melanoma metastases. Open Access Publications by UMMS Authors. https://doi.org/10.1016/j.jdcr.2019.03.015. Retrieved from https://escholarship.umassmed.edu/oapubs/3833
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Dermatology Commons, Hemic and Immune Systems Commons, Heterocyclic Compounds Commons, Neoplasms Commons, Pharmaceutical Preparations Commons, Skin and Connective Tissue Diseases Commons, Therapeutics Commons